• Adding Opdivo in First-Line Shows Promise in HER2+ Esophagogastric Cancer

    6 days ago - By MedPageToday

    A combination of the PD-1 inhibitor nivolumab plus trastuzumab and chemotherapy was effective as first-line therapy for patients with HER2 -positive esophagogastric adenocarcinoma, according to results...
    Read more ...